GSK Faces Industry Heat as UK Regulator Flags Misleading Claims on Omjjara

GlaxoSmithKline (GSK) is under serious scrutiny after a UK pharmaceutical watchdog determined the company violated industry standards by promoting inaccurate prescription information for its blood disorder drug Omjjara. The complaint, upheld by the Prescription Medicines Code of Practice Authority (PMCPA), accuses GSK of misleading healthcare professionals about the drug’s approval status and indications.

The PMCPA concluded that GSK breached multiple clauses of the industry’s marketing code, including failing to clearly distinguish between approved and unapproved indications. GSK’s promotional materials, intended for UK healthcare professionals, were found to imply that Omjjara was approved for myelofibrosis patients with severe thrombocytopenia, despite no such approval from UK regulators. This led to a level two breach, the more severe category under PMCPA’s compliance system.

The British pharma giant stated that it disagrees with aspects of the ruling but accepts the overall findings. It emphasized that corrective actions are being implemented, and the company is working closely with the PMCPA to prevent future violations. Omjjara, a Janus kinase (JAK) inhibitor, is used to treat certain rare blood cancers and was approved by the European Medicines Agency (EMA) in 2023 for use in adult patients with myelofibrosis.

This episode marks another blow to pharmaceutical industry credibility at a time when regulatory compliance and trust are under the microscope globally.